A lthough studies indicate that total body skin examination (TBSE) is an effective means to detect melanoma at an early, treatable stage, 1,2 the US Preventive Services Task Force concluded that current evidence was inadequate to evaluate the balance of benefits and harms of melanoma screening by TBSE. 3 Quantifying the cost of screening to the health care system is Abbreviations used:
confidence interval EMR: electronic medical record ICD:
International Classification of Diseases NMSC: nonmelanoma skin cancer NNB:
number needed to biopsy NNS: number needed to screen TBSE: total body skin examination important for drawing conclusions about the benefits and harms of screening. Cost effectiveness studies have been used to estimate and model societal costs and benefits of population melanoma screening projects; however, these have been predominantly done in the primary care or clinical trial setting. [4] [5] [6] [7] The practical cost of melanoma screening has not been well-studied in the United States in the setting of dermatology practices.
Using visits coded as skin cancer screening visits performed by dermatology practitioners at a large health care system with both academic and community-based providers, we aimed to determine the number needed to screen (NNS) and number needed to biopsy (NNB) to diagnose 1 skin cancer, the 2 standard metrics of screening efficacy, 8 as well as the cost per skin cancer diagnosed during TBSE.
METHODS
We identified all visits occurring at University of Pittsburgh Medical Centereaffiliated dermatology offices during January 1, 2011-December 31, 2015, in which skin cancer screening was performed using International Classification of Diseases Ninth or Tenth Revision (ICD-9 or ICD-10) diagnoses V76.43 (ICD-9) or Z12.83 (ICD-10), which code for encounter for screening for malignant neoplasm of the skin. To assess the accuracy of using ICD diagnoses in identifying TBSE visits, we used the following published methodology 9 : 100 eligible visits with and 100 eligible visits without these ICD-9 or ICD-10 diagnoses were randomly selected and charts were manually reviewed to calculate positive and negative predictive values.
Data extraction
For each identified visit, the visit and patient level data were extracted from the electronic medical record (EMR). Patient level data included sex, date of birth, race and ethnicity (self-reported), personal history of melanoma, and personal history of any skin cancer. The age at first dermatology visit was used. Age was subsequently dichotomized at 50 years of age because preliminary statistical analyses showed that melanoma risk increased at this age and for consistency with melanoma screening costeffectiveness studies. 6 Personal history of melanoma and of any skin cancer were determined using ICD-9 or ICD-10 codes (V10.82 or Z85.820 for melanoma, V10.83 or Z85.828 for nonmelanoma skin cancer, respectively) associated with current or prior visits, pathology reports containing melanoma diagnoses in our system, and EMR health history data. Visit level data included current procedural terminology codes, which can be used to determine the level of service for each visit and the procedures associated with that visit, including any codes used to denote lesion removal for pathologic examination (such as biopsy, shave, and excision) and preparation and examination of slides by a dermatopathologist. The Medicare physician fee schedule nonfacility cost was used to determine costs associated with each current procedural terminology code (Supplemental Table I ; available at http://www. jaad.org). 10 Pathology reports from all visits in which a skin lesion was removed for pathologic examination (on day of or up to 1 month after the office visit) were reviewed to categorize lesions as pigmented or nonpigmented and to obtain the diagnosis of the lesion removed.
Statistical analysis
Poisson regression was used to model counts of any skin cancer, melanoma, and nonmelanoma skin cancer (NMSC). NNS was calculated as the inverse of the absolute risk for skin cancer per patient visit in univariate regression models. NNB was calculated as the inverse of the absolute risk for skin cancer per patient biopsy in univariate regression models. Only pigmented lesion biopsies were used to calculate NNB for melanoma. Only nonpigmented lesion biopsies were used to calculate NNB for NMSC. All biopsies were used to calculate NNB for any skin cancer. Poisson regression was used with 1 observation per patient for both univariate and multivariable models. To adjust for patients with multiple visits and biopsies, an exposure variable corresponding to number of visits for NNS estimates and number of biopsies for NNB estimates were included. Mixed models were initially attempted; however, due to a high proportion of patients with a single visit and low number of melanomas diagnosed, these models did not converge. Stepwise regression was used to select factors from those
CAPSULE SUMMARY d
Total body skin examinations (TBSEs) by dermatologists might improve early skin cancer detection. In this study, the cost per melanoma detected during total body skin examination was $32,594 and was lower in older individuals and male patients. Patient-level data can be used to help model the cost-effectiveness of TBSEs by dermatologists.
significant in univariate models for multivariate models. Stepwise regression models included age, sex, and personal history of skin cancer and melanoma as potential covariates for selection in multivariable models and used a selection P value of\.05.
Patient biopsy rate was calculated as the number of visits in which a biopsy was performed divided by the total number of screening visits. Biopsy rate was calculated as the patient biopsy rate times the mean number of biopsies per patient who had biopsies performed. Chi-square tests were used to compare biopsy rate by age, sex, and personal history of skin cancer. Average visit cost was broken down into the cost of the office visit and biopsy costs, including dermatopathology costs. Student t test was used to compare visit costs by age, sex, and personal history of skin cancer. Normal bootstrap confidence intervals (CIs) were calculated for cost per cancer detected, and P values for comparisons were calculated by the permutation method. Cost per melanoma detected was calculated as NNS x mean cost per visit. All statistical analyses were performed in R version 3.3.1 (R Core Team, Vienna, Austria).
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Ethical considerations
This study was approved by the University of Pittsburgh Institutional Review Board (PRO16080018).
RESULTS
Population presenting for skin cancer screening
During the 5-year study period, 33,647 TBSEs were performed in 20,270 adult patients (age $18 years), with a mean of 1.66 TBSEs per patient. Patients with personal history of skin cancer were more likely to have multiple TBSEs during the study period (P \.001; Table I ).
Validation of identifying TBSEs by ICD diagnoses
Of the 100 randomly sampled records with ICD diagnoses V76.43 or Z10.43, a TBSE was performed in 97% of the visits on manual review of the electronic chart (positive predictive value 97%). Of the 100 randomly sampled records without these ICD diagnoses, a TBSE was performed in 17% of the visits on manual review of the electronic chart (negative predictive value 83%).
All skin cancers
In total, 2763 skin cancers were diagnosed from 9956 biopsies. For all skin cancers, NNS was 12.2 (95% CI 11.7-12.6) and NNB was 3.0 (95% CI 2.9-3.1) (Figs 1 and 2) . In univariate analysis, NNS and NNB were lower with increasing age, in men, and in patients with a personal history of any skin cancer (P \ .001 for all; Figs 1 and 2). Personal history of melanoma was also associated with lower NNB (P = .035). In multivariable models for NNS and NNB, age, sex, and skin cancer history remained significant factors after stepwise regression (P \ .001 for all; Table II ).
Melanoma skin cancers
In total, 155 melanomas were diagnosed from 4930 biopsies of pigmented lesions. Review of all melanoma cases showed that 81 of 156 (51.9%) were not identified as suspicious by the patient per chart history and, thus, were truly detected through TBSE. J AM ACAD DERMATOL VOLUME 78, NUMBER 4
Overall, the NNS was 215 (95% CI 185-252) and NNB was 27.8 (95% CI 23.3-33.3) to detect 1 melanoma (Figs 1 and 2) . In univariate models, NNS was lower with increasing age (P \.001), in men (P \.01), and in patients with a personal history of melanoma (P \.001) but not in patients with a personal history of any skin cancer (Fig 1) . In univariate modeling, age switches from a protective factor to a risk factor at 51 years of age. Increasing age (P \.001) and male sex (P\.01) were associated with lower NNB (Fig 2) . However, after controlling for age, male sex lost significance, and age was the only factor included in the regression model for NNB by stepwise selection.
In a multivariable model for NNS, age (P \.001) and personal history of melanoma (P \ .001) were significant factors (Table II) .
Nonmelanoma skin cancers
In total, 2607 NMSCs were diagnosed from 5026 biopsies for nonpigmented lesions. For NMSC, NNS was 12.9 (95% CI 12.4-13.4) and NNB was 1.6 (95% CI 1.5-1.7) (Figs 1 and 2) . In the univariate model, both NNS and NNB were lower with increasing age, in men, and in patients with a personal history of any skin cancer (P \.001 for all; Figs 1 and 2 ). Personal history of melanoma was also associated with lower NNB (P \.01). In the multivariable model, sex, age, and any skin cancer history remained significant factors (P \.001 for all; Table II) .
Costs of screening
The overall mean visit cost for a skin cancer screening was $150, consisting of $105 (70%) for the office visit and $45 (30%) for the biopsy and examination by a dermatopathologist (a value that accounts for the fact that a biopsy was not performed at every visit) ( Table III) . The biopsy rate per visit for all lesions was higher in men, patients $50 years of age, and patients with a personal history of skin cancer (Table III) . Pigmented lesion biopsy rate was highest in patients with a personal history of melanoma and patients \50 years of age.
The cost per melanoma detected was estimated to be $32,594 and $2496 per NMSC diagnosis Number needed to biopsy (NNB) for melanoma (top), nonmelanoma skin cancers (middle), and any skin cancers (bottom), by age and sex, at a dermatology clinic. The mean NNB and 95% confidence intervals (whiskers) are displayed. NNB indicates the number of biopsies required to diagnose 1 cancer of the given type. MelHx, Personal history of melanoma; SCHx, personal history of skin cancer.
J AM ACAD DERMATOL VOLUME 78, NUMBER 4 (Table III) . For melanoma, the point estimates of the cost of detection was higher for women than men (P = .043) and higher in patients #50 (P = .002). The lowest cost per melanoma detected was observed in patients with a personal history of melanoma at $15,714, which was significantly less than the cost of detection for patients without a history of melanoma (P \ .05) (Table III) . Given these findings, we looked specifically at cost of melanoma detection in men [50 years and found costs were significantly lower than in younger men and women (P \ .001 and P = .018, respectively). Cost per melanoma detection did not differ significantly in women \50 years versus $50 years (P = .258), in men versus women \50 years of age (P = .113), or in patients with versus without a personal history of any skin cancer (P = .495).
DISCUSSION
Our data from [33,000 TBSEs performed in dermatology offices in a large health care system show that screening is most efficient and least costly in the patients at higher risk for melanoma: those $50 years of age and with a history of previous melanoma. In our study population, the overall NNS was 215 and NNB was 27.8 to detect 1 melanoma, and the NNS was 12.9 and NNB was 1.6 for 1 case of NMSC. The NNS and NNB to detect 1 melanoma dropped above the age of 50 years in our population, suggesting that screening patients age 50 years and older is likely to yield a higher melanoma detection rate. TBSE in patients with a personal history of melanoma is high-yield with a cost per melanoma detected of less than half of that seen in the overall study population.
Our findings probably reflect the higher risk population evaluated in a dermatology versus primary care office. Data from 15 years of American Academy of Dermatology screenings by dermatologists found an NNS of 668 for each melanoma detected. 12 About 14% of those screened reported a history of skin cancer versus 25% in our population. 12 The German SCREEN (Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany) program, in which 360,288 people were screened primarily by primary care physicians, reported the NNS to find 1 melanoma was 620; fewer than 3% of the participants in this study reported a skin cancer history, and the NNB was 28. 13 Few studies have evaluated cost at the patient level. Gordon et al performed a patient-level cost analysis using data from an Australian clinical trial of skin screening.
14 Patients attended free screening clinics, and only those with suspicious lesions were referred for biopsy. A cost of $12,152 per melanoma detected can be derived from their data, but this value does not include the costs of all screening visits. Extrapolation from the data of Hoorens et al from 1668 screened patients show that the NNS and NNB to find 1 melanoma were 208.5 and 3.25, respectively, yielding a cost per melanoma diagnosed of $5346. 15 However, as these data were collected in the setting of a study on screening efficiency and not routine practice, biopsies performed at patient request were likely reduced.
Other studies using Markov models to attempt to quantify the cost-effectiveness of screening have found that screening strategies, such as a single screening of the general population or surveillance of high-risk patients in a specialized clinic, are cost effective. 6, 7, 16 Data such as ours can be useful for future modeling endeavors by providing valuable data from a real-world clinical setting in the United States. For example, in a study using a Belgian model on the cost-effectiveness of screening, a cost of $5.30 per screening was used. 7 In this study, if the costs of office visits observed in our cohort had been used, the study's findings would have been significantly different.
Although our approach allowed us to collect encounter-level data for a large number of visits, the use of this type of data has several limitations. Our analysis is limited to visits coded as visits for skin cancer screening and ;17% of TBSEs performed during the study period were not identified by this strategy, although the negative predictive value of 83% is within the range reported by other EMR studies (67.7%-100%). 9 We also do not know the degree of clinical suspicion for each biopsy performed, and if some were performed due to patient request rather than strong suspicion for skin cancer. Our analysis did not account for additional downstream screening costs, such as treatment costs for skin cancers or other lesions (eg, actinic keratoses) diagnosed during screening. Also, our data are reflective of TBSE for early detection and cannot necessarily be translated to population-based screening, as our dermatology-based population would be considered higher risk due to the large percentage of patients with a personal history of skin cancer. Screening of the asymptomatic general population would likely be more expensive due to lower disease prevalence.
In our study, office visits contributed to most screening costs, and only 0.46% of these visits result in a melanoma diagnosis. One way to reduce the cost per melanoma detected is to increase melanoma prevalence in the screened population. This can be accomplished by selective screening by specific criteria: 1) age and sex; 2) personal history of melanoma; or 3) prescreening by strategies such as self-examination, trained partner examination, or community-based screening. 1, 6, 8, 15, 17, 18 Increasing biopsy sensitivity will also reduce the cost per melanoma diagnosed. Strategies shown to achieve this include provider training programs and routine use of dermoscopy. 18, 19 Few studies have attempted to measure the cost per cancer detected. In a study of mammography in Medicare beneficiaries, the cost per breast cancer diagnosed was $16,524 among women 66-74 years of age, a number similar to our cost per melanoma diagnosis in our highest risk patient groups ($50 years of age and patients with a personal history of melanoma). 20 Our data support targeting high-risk populations for screening by dermatologists. Population-based screening in a primary care setting with subsequent referral to a dermatology clinic for suspicious lesions could offer a more cost-effective alternative for screening of lower risk patients 21, 22 by increasing the pretest probability of melanoma in the population examined by dermatologists while leveraging the higher diagnostic accuracy of dermatologists; this strategy would reduce both missed melanomas and unnecessary biopsies of benign lesions.
